MENU
+Compare
CMOPF
Stock ticker: OTC
AS OF
Dec 24 closing price
Price
$133.50
Change
+$0.25 (+0.19%)
Capitalization
2.13B

CMOPF stock forecast, quote, news & analysis

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech... Show more

CMOPF
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for CMOPF with price predictions
Dec 24, 2025

CMOPF's RSI Oscillator is staying in overbought zone for 15 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Aroon Indicator for CMOPF entered a downward trend on December 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 23, 2025. You may want to consider a long position or call options on CMOPF as a result. In of 22 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CMOPF just turned positive on December 03, 2025. Looking at past instances where CMOPF's MACD turned positive, the stock continued to rise in of 19 cases over the following month. The odds of a continued upward trend are .

CMOPF moved above its 50-day moving average on December 03, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CMOPF crossed bullishly above the 50-day moving average on December 03, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 7 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.920) is normal, around the industry mean (9.054). P/E Ratio (31.715) is within average values for comparable stocks, (24.434). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.056). Dividend Yield (0.018) settles around the average of (0.026) among similar stocks. CMOPF's P/S Ratio (10.152) is slightly higher than the industry average of (3.759).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CMOPF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 104.36B. The market cap for tickers in the group ranges from 72.83K to 963.92B. LLY holds the highest valuation in this group at 963.92B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 2%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 15%. CSPCY experienced the highest price growth at 16%, while SCLX experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -56%. For the same stocks of the Industry, the average monthly volume growth was -74% and the average quarterly volume growth was -65%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 30
P/E Growth Rating: 62
Price Growth Rating: 52
SMR Rating: 57
Profit Risk Rating: 73
Seasonality Score: 21 (-100 ... +100)
View a ticker or compare two or three
CMOPF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
Sir John Rogerson’s Quay
Phone
+353 18170370
Employees
295
Web
https://www.cosmopharma.com